Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.328,97
-0,91%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mirati Therapeutics Inc (MRTX) Mirati Therapeutics Inc (MRTX) Notizie

MRTX

Mirati Therapeutics (MRTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MRTX
DataOraFonteTitoloSimboloCompagnia
14/02/202420:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRTXMirati Therapeutics Inc
02/02/202422:05Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MRTXMirati Therapeutics Inc
25/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRTXMirati Therapeutics Inc
24/01/202402:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415:31Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415:30Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202414:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRTXMirati Therapeutics Inc
10/01/202414:00PR Newswire (US)European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
27/12/202322:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
06/12/202314:29Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MRTXMirati Therapeutics Inc
10/11/202313:30PR Newswire (US)Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedureNASDAQ:MRTXMirati Therapeutics Inc
06/11/202314:00PR Newswire (US)Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:MRTXMirati Therapeutics Inc
06/11/202313:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRTXMirati Therapeutics Inc
03/11/202322:19PR Newswire (US)Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
02/11/202312:30Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
02/11/202312:30GlobeNewswire Inc.Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNASDAQ:MRTXMirati Therapeutics Inc
23/10/202323:31Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
17/10/202322:00PR Newswire (US)Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)NASDAQ:MRTXMirati Therapeutics Inc
09/10/202316:30Dow Jones NewsTrending: Bristol Myers Squibb Buying Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
09/10/202313:33IH Market NewsMonday’s Wall Street Highlights: Exxon Mobil, Bristol-Myers, Disney, Lockheed Martin, and moreNASDAQ:MRTXMirati Therapeutics Inc
09/10/202312:26Dow Jones NewsMirati Shares Slip Premarket on Bristol Myers TakeoverNASDAQ:MRTXMirati Therapeutics Inc
09/10/202301:21KR Market News브리스톨-마이어스 스퀴브, 48억 달러에 미라티 인수NASDAQ:MRTXMirati Therapeutics Inc
09/10/202300:02Business WireBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202308:56Dow Jones NewsSanofi Considering Acquisition of Mirati Therapeutics, Bloomberg ReportsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202302:33KR Market News사노피, 항암제 제조사 미라티 인수 검토 – 외신NASDAQ:MRTXMirati Therapeutics Inc
05/10/202322:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRTXMirati Therapeutics Inc
02/10/202322:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRTXMirati Therapeutics Inc
27/09/202322:30PR Newswire (US)Mirati To Present Updated Clinical Data at ESMO Congress 2023NASDAQ:MRTXMirati Therapeutics Inc
10/09/202304:35PR Newswire (US)Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung CancerNASDAQ:MRTXMirati Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MRTX

La tua Cronologia

EU
XS1874729624
ABN Amro Bank NV 1.1% 29...
NYSE
SIG
Signet Jewelers
USOTC
OGSSS
Otis Gallery (PK)
USOTC
JBFCY
Jollibee Foods (PK)
DOWI
NCTY
BOV
NETE34
NetEase
GDAX
LINKEUR
ChainLink Token
COIN
RAKUCETH
Raku Coin
NASDAQ
BRPA
Big Rock Partners Acquis...
XE
3GLD
Leverage Shares Public
COIN
GRFTGBP
NASDAQ
TZPSW
TZP Strategies Acquisition
EU
0019N
Natixis S A null
GDAX
ATOMUSDT
Cosmos Atom
UPBT
POWRETH
PowerLedger
NASDAQ
MSFD
Direxion Daily MSFT
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network